Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Insights into Imaging
Published in: Insights into Imaging 1/2019

Open Access 01-12-2019 | Magnetic Resonance Imaging | Educational Review

Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review

Authors: Nicolas Voizard, Milena Cerny, Anis Assad, Jean-Sébastien Billiard, Damien Olivié, Pierre Perreault, Ania Kielar, Richard K. G. Do, Takeshi Yokoo, Claude B. Sirlin, An Tang

Published in: Insights into Imaging | Issue 1/2019

Login to get access

Abstract

Computed tomography (CT) and magnetic resonance imaging (MRI) play critical roles for assessing treatment response of hepatocellular carcinoma (HCC) after locoregional therapy. Interpretation is challenging because posttreatment imaging findings depend on the type of treatment, magnitude of treatment response, time interval after treatment, and other factors. To help radiologists interpret and report treatment response in a clear, simple, and standardized manner, the Liver Imaging Reporting and Data System (LI-RADS) has developed a Treatment Response (LR-TR) algorithm. Introduced in 2017, the system provides criteria to categorize response of HCC to locoregional treatment (e.g., chemical ablation, energy-based ablation, transcatheter therapy, and radiation therapy). LR-TR categories include Nonevaluable, Nonviable, Equivocal, and Viable. LR-TR does not apply to patients on systemic therapies. This article reviews the LR-TR algorithm; discusses locoregional therapies for HCC, treatment concepts, and expected posttreatment findings; and illustrates LI-RADS treatment response assessment with CT and MRI.
Literature
1.
2.
Kielar A, Fowler KJ, Lewis S et al (2018) Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol (NY) 43:218–230CrossRef
3.
Tang A, Fowler KJ, Chernyak V, Chapman WC, Sirlin CB (2018) LI-RADS and transplantation for hepatocellular carcinoma. Abdom Radiol (NY) 43:193–202CrossRef
4.
Chernyak V, Fowler KJ, Kamaya A et al (2018) Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 289:816–830PubMedCrossRef
5.
6.
Ahmed M, Solbiati L, Brace CL et al (2014) Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. Radiology 273:241–260PubMedCrossRef
7.
Gaba RC, Lewandowski RJ, Hickey R et al (2016) Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 27:457–473PubMedCrossRef
8.
Guan YS, Sun L, Zhou XP, Li X, Zheng XH (2004) Hepatocellular carcinoma treated with interventional procedures: CT and MRI follow-up. World J Gastroenterol 10:3543–3548PubMedPubMedCentralCrossRef
9.
Joseph FB, Baumgarten DA, Bernardino ME (1993) Hepatocellular carcinoma: CT appearance after percutaneous ethanol ablation therapy. Work in progress. Radiology 186:553–556PubMedCrossRef
10.
Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC (2005) Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 54:1151–1156PubMedPubMedCentralCrossRef
11.
Shiina S, Teratani T, Obi S et al (2005) A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129:122–130PubMedCrossRef
12.
Stauffer PR, Goldberg SN (2004) Introduction: thermal ablation therapy. Int J Hyperthermia 20:671–677PubMedCrossRef
13.
Goldberg SN, Gazelle GS, Mueller PR (2000) Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol 174:323–331PubMedCrossRef
14.
Thompson SM, Callstrom MR, Butters KA et al (2014) Heat stress induced cell death mechanisms in hepatocytes and hepatocellular carcinoma: in vitro and in vivo study. Lasers Surg Med 46:290–301PubMedPubMedCentralCrossRef
15.
Goldberg SN, Stein MC, Gazelle GS, Sheiman RG, Kruskal JB, Clouse ME (1999) Percutaneous radiofrequency tissue ablation: optimization of pulsed-radiofrequency technique to increase coagulation necrosis. J Vasc Interv Radiol 10:907–916PubMedCrossRef
16.
Lin ZY, Li GL, Chen J, Chen ZW, Chen YP, Lin SZ (2016) Effect of heat sink on the recurrence of small malignant hepatic tumors after radiofrequency ablation. J Cancer Res Ther 12:C153–C158PubMedCrossRef
17.
Poulou LS, Botsa E, Thanou I, Ziakas PD, Thanos L (2015) Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Hepatol 7:1054–1063PubMedPubMedCentralCrossRef
18.
Simon CJ, Dupuy DE, Mayo-Smith WW (2005) Microwave ablation: principles and applications. Radiographics 25(Suppl 1):S69–S83PubMedCrossRef
19.
Wright AS, Lee FT Jr, Mahvi DM (2003) Hepatic microwave ablation with multiple antennae results in synergistically larger zones of coagulation necrosis. Ann Surg Oncol 10:275–283PubMedCrossRef
20.
Mulier S, Mulier P, Ni Y et al (2002) Complications of radiofrequency coagulation of liver tumours. Br J Surg 89:1206–1222PubMedCrossRef
21.
Nakagomi R, Tateishi R, Shiina S et al (2014) Drastically reduced neoplastic seeding related to radiofrequency ablation for hepatocellular carcinoma. Am J Gastroenterol 109:774–776PubMedCrossRef
22.
Rhim H (2005) Complications of radiofrequency ablation in hepatocellular carcinoma. Abdom Imaging 30:409–418PubMedCrossRef
23.
Yang B, Zan RY, Wang SY et al (2015) Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials. World J Surg Oncol 13:96PubMedPubMedCentralCrossRef
24.
Brunello F, Veltri A, Carucci P et al (2008) Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 43:727–735PubMedCrossRef
25.
Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC (2004) Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 127:1714–1723PubMedCrossRef
26.
Lu MD, Kuang M, Liang LJ et al (2006) Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial. Zhonghua Yi Xue Za Zhi 86:801–805PubMed
27.
Chen MS, Li JQ, Zheng Y et al (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243:321–328PubMedPubMedCentralCrossRef
28.
Kutlu OC, Chan JA, Aloia TA et al (2017) Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma. Cancer 123:1817–1827CrossRefPubMed
29.
30.
European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236
31.
Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750PubMedCrossRef
32.
Vietti Violi N, Duran R, Guiu B et al (2018) Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. Lancet Gastroenterol Hepatol 3:317–325PubMedCrossRef
33.
Lencioni R, de Baere T, Martin RC, Nutting CW, Narayanan G (2015) Image-guided ablation of malignant liver tumors: recommendations for clinical validation of novel thermal and non-thermal technologies - a Western perspective. Liver Cancer 4:208–214PubMedPubMedCentralCrossRef
34.
35.
Oei T, vanSonnenberg E, Shankar S, Morrison PR, Tuncali K, Silverman SG (2005) Radiofrequency ablation of liver tumors: a new cause of benign portal venous gas. Radiology 237:709–717PubMedCrossRef
36.
Kim KW, Lee JM, Choi BI (2011) Assessment of the treatment response of HCC. Abdom Imaging 36:300–314PubMedCrossRef
37.
Park YN, Yang CP, Fernandez GJ, Cubukcu O, Thung SN, Theise ND (1998) Neoangiogenesis and sinusoidal “capillarization” in dysplastic nodules of the liver. Am J Surg Pathol 22:656–662PubMedCrossRef
38.
Yasui D, Murata S, Ueda T et al (2018) Novel treatment strategy for advanced hepatocellular carcinoma: combination of conventional transcatheter arterial chemoembolization and modified method with portal vein occlusion for cases with arterioportal shunt: a preliminary study. Acta Radiol 59:266–274PubMedCrossRef
39.
Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52PubMedCrossRef
40.
Liu DM, Salem R, Bui JT et al (2005) Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 16:911–935PubMedCrossRef
41.
42.
Terzi E, Ray Kim W, Sanchez W et al (2015) Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl 21:248–257PubMedCrossRef
43.
Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442PubMedCrossRef
44.
Raoul JL, Gilabert M, Piana G (2014) How to define transarterial chemoembolization failure or refractoriness: a European perspective. Liver Cancer 3:119–124PubMedPubMedCentralCrossRef
45.
Brown KT, Do RK, Gonen M et al (2016) Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 34:2046–2053PubMedPubMedCentralCrossRef
46.
Sangro B (2014) Chemoembolization and radioembolization. Best Pract Res Clin Gastroenterol 28:909–919PubMedCrossRef
47.
Zivin SP, Elias Y, Ray CE Jr (2015) Tumor lysis syndrome and primary hepatic malignancy: case presentation and review of the literature. Semin Intervent Radiol 32:3–9PubMedPubMedCentralCrossRef
48.
Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D (2009) Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 20:S317–S323PubMedCrossRef
49.
Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171PubMedCrossRef
50.
Lewis AL, Gonzalez MV, Lloyd AW et al (2006) DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17:335–342PubMedCrossRef
51.
Facciorusso A, Mariani L, Sposito C et al (2016) Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 31:645–653PubMedCrossRef
52.
Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6–25PubMedCrossRef
53.
Kwan SW, Fidelman N, Ma E, Kerlan RK Jr, Yao FY (2012) Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl 18:727–736PubMedPubMedCentralCrossRef
54.
Bisseret D, Ronot M, Abdel-Rehim M et al (2013) Intratumoral gas in hepatocellular carcinoma following transarterial chemoembolization: associated factors and clinical impact. J Vasc Interv Radiol 24:1623–1631PubMedCrossRef
55.
Salem R, Mazzaferro V, Sangro B (2013) Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology 58:2188–2197PubMedCrossRef
56.
Park MJ, Kim SY, Yoon SM et al (2014) Stereotactic body radiotherapy-induced arterial hypervascularity of non-tumorous hepatic parenchyma in patients with hepatocellular carcinoma: potential pitfalls in tumor response evaluation on multiphase computed tomography. PLoS One 9:e90327PubMedPubMedCentralCrossRef
57.
Potters L, Kavanagh B, Galvin JM et al (2010) American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 76:326–332PubMedCrossRef
58.
Schaub SK, Hartvigson PE, Lock MI et al (2018) Stereotactic body radiation therapy for hepatocellular carcinoma: current trends and controversies. Technol Cancer Res Treat 17:1533033818790217PubMedPubMedCentralCrossRef
59.
Kimura T, Takahashi S, Takahashi I et al (2015) The time course of dynamic computed tomographic appearance of radiation injury to the cirrhotic liver following stereotactic body radiation therapy for hepatocellular carcinoma. PLoS One 10:e0125231PubMedPubMedCentralCrossRef
60.
61.
Kimura T, Takahashi S, Kenjo M et al (2013) Dynamic computed tomography appearance of tumor response after stereotactic body radiation therapy for hepatocellular carcinoma: how should we evaluate treatment effects? Hepatol Res 43:717–727PubMedCrossRef
62.
Lo SS, Dawson LA, Kim EY et al (2010) Stereotactic body radiation therapy for hepatocellular carcinoma. Discov Med 9:404–410PubMed
63.
Liang SX, Zhu XD, Xu ZY et al (2006) Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 65:426–434PubMedCrossRef
64.
Benson R, Madan R, Kilambi R, Chander S (2016) Radiation induced liver disease: a clinical update. J Egypt Natl Canc Inst 28:7–11PubMedCrossRef
65.
Hamami ME, Poeppel TD, Muller S et al (2009) SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer. J Nucl Med 50:688–692PubMedCrossRef
66.
Salem R, Parikh P, Atassi B et al (2008) Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol 31:431–438PubMedCrossRef
67.
Spina JC, Hume I, Pelaez A, Peralta O, Quadrelli M, Garcia Monaco R (2019) Expected and unexpected imaging findings after (90) Y transarterial radioembolization for liver tumors. Radiographics 39:578–595PubMedCrossRef
68.
Hamoui N, Minocha J, Memon K et al (2013) Prophylactic embolization of the gastroduodenal and right gastric arteries is not routinely necessary before radioembolization with glass microspheres. J Vasc Interv Radiol 24:1743–1745PubMedCrossRef
69.
Kim YC, Kim YH, Uhm SH et al (2010) Radiation safety issues in y-90 microsphere selective hepatic radioembolization therapy: possible radiation exposure from the patients. Nucl Med Mol Imaging 44:252–260PubMedPubMedCentralCrossRef
70.
Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C (2004) Pathologic response and microdosimetry of (90) Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60:1552–1563PubMedCrossRef
71.
Sangro B, Inarrairaegui M, Bilbao JI (2012) Radioembolization for hepatocellular carcinoma. J Hepatol 56:464–473PubMedCrossRef
72.
Gil-Alzugaray B, Chopitea A, Inarrairaegui M et al (2013) Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 57:1078–1087PubMedCrossRef
73.
Sangro B, Gil-Alzugaray B, Rodriguez J et al (2008) Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112:1538–1546PubMedCrossRef
74.
Wahl DR, Stenmark MH, Tao Y et al (2016) Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 34:452–459PubMedCrossRef
75.
Yoon SM, Lim YS, Park MJ et al (2013) Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma. PLoS One 8:e79854PubMedPubMedCentralCrossRef
76.
Sapisochin G, Barry A, Doherty M et al (2017) Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma An intention-to-treat analysis. J Hepatol 67:92–99PubMedCrossRef
77.
78.
Bujold A, Massey CA, Kim JJ et al (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 31:1631–1639PubMedCrossRef
79.
Salem R, Gordon AC, Mouli S et al (2016) Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 151(1155–1163):e1152
80.
Facciorusso A, Serviddio G, Muscatiello N (2016) Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: a systematic review and meta-analysis. World J Hepatol 8:770–778PubMedPubMedCentralCrossRef
81.
Parikh ND, Waljee AK, Singal AG (2015) Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl 21:1142–1152PubMedCrossRef
82.
Salem R, Gabr A, Riaz A et al (2018) Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology 68:1429–1440PubMedCrossRef
83.
Atassi B, Bangash AK, Bahrani A et al (2008) Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics 28:81–99PubMedCrossRef
84.
85.
Cerny M, Bergeron C, Billiard JS et al (2018) LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Radiology 288:118–128PubMedCrossRef
Metadata
Title
Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review
Authors
Nicolas Voizard
Milena Cerny
Anis Assad
Jean-Sébastien Billiard
Damien Olivié
Pierre Perreault
Ania Kielar
Richard K. G. Do
Takeshi Yokoo
Claude B. Sirlin
An Tang
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
Insights into Imaging / Issue 1/2019
Electronic ISSN: 1869-4101
DOI
https://doi.org/10.1186/s13244-019-0801-z

Other articles of this Issue 1/2019

Insights into Imaging 1/2019 Go to the issue

Review

Techniques and future perspectives for the prevention and treatment of endoleaks after endovascular repair of abdominal aortic aneurysms

Review

Pathology of the carotid space

Educational Review

Imaging of shoulder arthroplasties and their complications: a pictorial review

Statement

The current status of radiological clinical audit - an ESR Survey of European National Radiology Societies

Review

Reconstruction techniques for cardiac cine MRI

Pictorial Review

Dynamic magnetic resonance imaging of the female pelvic floor—a pictorial review